It is of note that regulation of ferrochelatase activity has proven in recent years to be imperative, as several researchers are exploring the aspects of ferrochelatase inhibition with small-molecule inhibitors for therapeutic purposes in the treatment of cancers, ocular angiogenesis, and parasitic infections. This evidence concerns the gene FECH and cancer.